Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
Editorial

The Legacy of CVI

Marcela F. Pasetti, Steven D. Douglas, Susan F. Plaeger
Christopher J. Papasian, Editor
Marcela F. Pasetti
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven D. Douglas
bDepartment of Pediatrics, Division of Allergy-Immunology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan F. Plaeger
cBasic Sciences Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Papasian
University of Missouri—Kansas City School of Medicine
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CVI.00276-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Clinical and Vaccine Immunology (CVI) will merge with the American Society for Microbiology (ASM) open-access journal mSphere in January 2018. We commemorate this transition by exploring the history of CVI and that of its predecessor, Clinical and Diagnostic Laboratory Immunology (CDLI), and by acknowledging their contributors. Research on vaccines, clinical immunology, and clinical diagnostic immunology published through mSphere will be available without restrictions to an ever-larger audience, which will expedite progress in the field. ASM remains committed to supporting its members and the research community by facilitating the dissemination of scientific knowledge in these important areas.

The views expressed in this Editorial do not necessarily reflect the views of the journal or of ASM.

EDITORIAL

Clinical and Vaccine Immunology (CVI) begins a new phase as it merges with the American Society of Microbiology (ASM) journal mSphere in January 2018. The time is appropriate to look at the history of the journal and its contribution to the scientific community. Most importantly, it is an opportunity to acknowledge those who have accompanied us and advanced CVI's mission: authors, editors, editorial board members, reviewers, ASM staff, ASM members, and the enduringly supportive research community, to whom we are most sincerely grateful.

Clinical and Diagnostic Laboratory Immunology

The journey started in January of 1994, when Clinical and Diagnostic Laboratory Immunology (CDLI) was launched (Fig. 1). During this time, the number of clinical immunology laboratories expanded due to the increased demand for immunologically based diagnostic tests for infectious diseases and clinical laboratory assessment of immune cell competency. Practices for standardization, quality control, and quality assurance matured simultaneously, along with the expectation of high-quality clinical laboratory standards. As the area of diagnostic laboratory immunology expanded, the Publications Board of ASM recognized the need for a journal exclusively dedicated to clinical laboratory immunology. With Dr. Steven D. Douglas as founding editor in chief (1994 to 2003), CDLI was established to facilitate dissemination of the growing body of research in the field (1). Indeed, the following decade witnessed major scientific advances in cellular immunology, molecular genetics, and immunodiagnostics. Diagnostic immunology evolved from the identification of antibodies resulting from infection to a variety of new assays using polyclonal and monoclonal antibodies to detect microbial antigens in body fluids and more-sophisticated methods for detecting antigen expression in tissue (2). Remarkable progress was also made in cellular immunology, particularly in the areas of immune deficiency, autoimmunity, inflammatory diseases, and immunopathogenesis. In vitro alternatives to skin testing for tuberculosis were developed, and flow cytometry and other methods for assessing immune function were increasingly utilized. These breakthroughs led to laboratory automation in diagnostic immunology (3). A series of commentaries by Isenberg, Rose, Fahey, Tomar, and Douglas, published in the June 1999 issue of CDLI, summarize some of these milestones (1–5). Over this period, CDLI became a highly cited source within the field of medical laboratory immunology.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Timeline of ASM clinical immunology and vaccine publications.

Clinical and Vaccine Immunology: Expanded Scope and a New Name

In parallel with improvements in disease diagnostics, the ongoing HIV/AIDS epidemic and new threats of bioterrorism and emerging infectious disease agents emphasized the need for disease prevention. The development and evaluation of new vaccines gained prominence in the fields of immunology and microbiology and with the public at large. Aiming to better support ASM members and the vaccine and immunology communities in general, CDLI's editor in chief, Dr. Susan F. Plaeger (2003 to 2013) spearheaded an expansion of the journal's scope. The concept of broadening the areas of interest to include a wider range of immunology, as well as vaccinology, received support from ASM's Immunology Division members, ASM's Academy of Microbiology members, and the previous editor in chief, Dr. Steven D. Douglas. In 2005, the ASM Publications Board approved the new scope and name, Clinical and Vaccine Immunology, with its first issue appearing in January of 2006 (Fig. 1). By this time, the journal had also gone from bimonthly to monthly publication. These changes resulted in a steady increase in the journal's reputation and its nomination by Thomson Reuters' ScienceWatch as a Rising Star in the field of immunology for several consecutive years (6). Around 2010, ASM Journals transitioned to an online eJournalPress (eJP) system, leading to substantial improvements in the submission, review, and publication processes. At the time, CVI was also published exclusively online. Despite the logistical challenges of this growing phase, CVI editors, reviewers, and authors moved almost seamlessly into the new electronic era.

A Springtime for CVI

The publishing landscape has changed dramatically over the past several years. New journals emerged, presenting authors with more options for publishing their work (7). While some of these new venues pursued less rigorous standards, the quality and scientific merit of manuscripts remained CVI's top priority for publication (7). On a positive side, this intense competition propelled change and innovation.

New initiatives reinvigorated and increased CVI's visibility under editor in chief Marcela F. Pasetti (2013 to 2017). Three new sections, Spotlights, CVInsights, and Meeting Highlights, were added to showcase our best publications and to communicate expert opinions on timely, relevant, and controversial topics, as well as recent advances and research trends discussed at theme-specific meetings (7). CVI was also given a fresh look: a new cover design featuring scientific art from papers published in each issue. The Minireview section dramatically expanded through the leadership of Minireview editor Christopher Papasian, featuring several high-profile contributions.

Personalized medicine, trained immunity, rational vaccine design, novel adjuvants, maternal immunization, and immunotherapy were at the forefront of scientific advances during this period. Innovation in laboratory methods included multiplex technology, microarrays, single-cell analysis, immunoproteomics, mass spectrometry for analysis of antibodies, and point-of-care diagnostics, among others. There has been a renewed interest in controlled human infection challenge models to evaluate vaccine efficacy. The quest for elusive immune correlates of protection continued, making use of newer technology and statistical modeling approaches. The fascinating interplay between the microbiome, immune development and competency, and mother-child health gained greater attention. The relevance of sex as a biological variable and rigor of experimental approaches were emphasized. Important reports on these and other trending topics were published in CVI (8–14). In this rapidly expanding scientific environment, CVI remained committed to disseminating discoveries and scientific knowledge with high scholarly and editorial standards, in line with those of other ASM journals and following the tradition and excellence of the society itself. Mindful of the faster pace of our times and the demands on scientists today, CVI further simplified and expedited the entire publication process. A challenge CVI shared with other specialty journals has been the decline in submissions (15). This may reflect, in part, the proliferation of new journals and heightened competition, reliance on traditional (although flawed) metrics of impact (16), and an increasingly difficult research funding environment. Unconventional ways of communicating research gained popularity with the support of digital and information technology, such as podcasts, publication in video journals (17), and posting of manuscripts in repositories as “preprints” ahead of peer review (18). Another major trend with strong growth supported by authors, academic institutions, and major research sponsors has been unrestricted open-access publication.

CVI and mSphere

The research enterprise has become multi- and interdisciplinary and global. Rapid means of communication and easy access to information are essential to disseminating knowledge and key to facilitating progress. Biomedical research is a major force shaping and improving modern life. A new phase begins for CVI as it merges with the ASM journal mSphere (Fig. 1) after this last December 2017 issue. mSphere embodies the future of scholarly publishing by offering authors the opportunity for rapid publication of high-quality scientific reports across the field of microbiology in an open-access format (19). The research community will benefit from manuscripts being freely available to readers everywhere. Authors who wish to be more engaged in the publication process may find the mSphereDirect option to be attractive. This new track encourages authors to submit their articles to two external reviewers, respond to their critiques, and submit the reviews, the author's responses, and the revised manuscript to mSphere, whose editorial board will make a final decision within 5 days (20). Both the traditional and mSphereDirect tracks are supported by a robust editorial and peer review mechanism and ASM's highest publication standards. One of the primary goals of mSphere (a vision shared by other ASM journals) is to improve the authors' experience, making it as painless as possible, and to empower the authors to “be in control” (15, 19). mSphere also has a strong presence in social media that appeals to younger scientists. Manuscripts that would have previously been published in CVI will have a new home in mSphere. Under the exceptional leadership of founding editor in chief Michael Imperiale, mSphere is an excellent platform for publishing cutting-edge vaccine and clinical immunology research. Reaching an ever-larger readership, discoveries in these areas can have greater impact than ever before. The majority of current CVI editors have joined the enthusiastic mSphere editorial team and are looking forward to continuing to assist ASM members and the broader research community through this new venue.

In Appreciation

Finally, we express our heartfelt appreciation to the authors who entrusted us with their work, the editors who skillfully handled manuscripts and helped authors (Table 1), Editorial Board members, and reviewers who contributed their time, effort, and expertise to ensure high standards of quality in our publications; those who most frequently reviewed papers since 2010 made it into CVI's Hall of Fame (Table 2). We are further indebted to ASM's production editors (Table 3), assistant production editors (Table 4), and editorial assistants, who handled the editorial and publication process quietly and efficiently from behind the scenes. Many thanks to Henry D. Isenberg, former editor in chief of the Journal of Clinical Microbiology (1979 to 1989), who had a leading role in the establishment of CDLI. Thank you also to ASM Publications Board chairs Barbara H. Iglewski (1990 to 1999) and Samuel Kaplan (1999 to 2008), to Journals Board chair Tom Shenk (2008 to 2017), a cheerful supporter of CVI, to Linda M. Illig (director of ASM Journals, 1991–2007), and to Barbara M. Goldman (director of ASM Journals, 2008–2018), as well as to Melissa Junior (assistant director of ASM Journals, 2011-present), all of whom helped us through the many transitions of CDLI to CVI to mSphere over the last 23 years. Lastly, we are grateful to Christopher J. Papasian, Jessica Kanotz, and ASM Journals Board chair Patrick D. Schloss (2017–2027) for critically reviewing the manuscript.

View this table:
  • View inline
  • View popup
TABLE 1

CVI editors

View this table:
  • View inline
  • View popup
TABLE 2

The CVI Reviewer Hall of Fame: the most frequent CVI reviewers from 2010 to 2017

View this table:
  • View inline
  • View popup
TABLE 3

Production editors

View this table:
  • View inline
  • View popup
TABLE 4

Assistant production editors

It has been a privilege to be part of the ASM family and of this journal. See you all in mSphere.

  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Douglas SD
    . 1999. Clinical and diagnostic laboratory immunology: evolution of the field and birth of a journal. Clin Diagn Lab Immunol6:286.
    OpenUrl
  2. 2.↵
    1. Rose NR
    . 1999. Genesis and evolution of diagnostic and clinical immunology. Clin Diagn Lab Immunol6:289–290.
    OpenUrl
  3. 3.↵
    1. Tomar R
    . 1999. Total laboratory automation and diagnostic immunology. Clin Diagn Lab Immunol6:293–294.
    OpenUrlPubMed
  4. 4.↵
    1. Fahey JL
    . 1999. Clinical laboratory immunology: the future. Clin Diagn Lab Immunol6:291–292.
    OpenUrlPubMed
  5. 5.↵
    1. Isenberg HD
    . 1999. Microbiology and immunology: parent and (adult) offspring. Clin Diagn Lab Immunol6:287–288.
    OpenUrl
  6. 6.↵
    1. Anonymous
    . 2011. Microbe magazine. ASM News6:363–364.
    OpenUrl
  7. 7.↵
    1. Pasetti MF
    . 2016. Springtime for CVI. Clin Vaccine Immunol23:247. doi:10.1128/CVI.00102-16.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Hofmann D,
    2. Lai JR
    . 2017. Exploring human antimicrobial antibody responses on a single B cell level. Clin Vaccine Immunol24:e00544-16. doi:10.1128/CVI.00544-16.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Chakraborty S,
    2. Harro C,
    3. DeNearing B,
    4. Ram M,
    5. Feller A,
    6. Cage A,
    7. Bauers N,
    8. Bourgeois AL,
    9. Walker R,
    10. Sack DA
    . 2015. Characterization of mucosal immune responses to enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407. Clin Vaccine Immunol23:55–64. doi:10.1128/CVI.00617-15.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Skinner JA,
    2. Zurawski SM,
    3. Sugimoto C,
    4. Vinet-Oliphant H,
    5. Vinod P,
    6. Xue Y,
    7. Russell-Lodrigue K,
    8. Albrecht RA,
    9. Garcia-Sastre A,
    10. Salazar AM,
    11. Roy CJ,
    12. Kuroda MJ,
    13. Oh S,
    14. Zurawski G
    . 2014. Immunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment. Clin Vaccine Immunol21:1668–1680. doi:10.1128/CVI.00547-14.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Rhodes SJ,
    2. Sarfas C,
    3. Knight GM,
    4. White A,
    5. Pathan AA,
    6. McShane H,
    7. Evans TG,
    8. Fletcher H,
    9. Sharpe S,
    10. White RG
    . 2017. Using data from macaques to predict gamma interferon responses after Mycobacterium bovis BCG vaccination in humans: a proof-of-concept study of immunostimulation/immunodynamic modeling methods. Clin Vaccine Immunol24:e00525-16. doi:10.1128/CVI.00525-16.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Jensen K,
    2. Dela Pena-Ponce MG,
    3. Piatak M Jr,
    4. Shoemaker R,
    5. Oswald K,
    6. Jacobs WR Jr,
    7. Fennelly G,
    8. Lucero C,
    9. Mollan KR,
    10. Hudgens MG,
    11. Amedee A,
    12. Kozlowski PA,
    13. Estes JD,
    14. Lifson JD,
    15. Van Rompay KK,
    16. Larsen M,
    17. De Paris K
    . 2017. Balancing trained immunity with persistent immune activation and the risk of simian immunodeficiency virus infection in infant macaques vaccinated with attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG vaccine. Clin Vaccine Immunol24:e00360-16. doi:10.1128/CVI.00360-16.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Excler JL,
    2. Ake J,
    3. Robb ML,
    4. Kim JH,
    5. Plotkin SA
    . 2014. Nonneutralizing functional antibodies: a new “old” paradigm for HIV vaccines. Clin Vaccine Immunol21:1023–1036. doi:10.1128/CVI.00230-14.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Diago-Navarro E,
    2. Calatayud-Baselga I,
    3. Sun D,
    4. Khairallah C,
    5. Mann I,
    6. Ulacia-Hernando A,
    7. Sheridan B,
    8. Shi M,
    9. Fries BC
    . 2017. Antibody-based immunotherapy to treat and prevent infection with hypervirulent Klebsiella pneumoniae. Clin Vaccine Immunol24:e00456-16. doi:10.1128/CVI.00456-16.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Schloss PD,
    2. Johnston M,
    3. Casadevall A
    . 2017. Support science by publishing in scientific society journals. mBio8:e01633-17. doi:10.1128/mBio.01633-17.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Casadevall A,
    2. Bertuzzi S,
    3. Buchmeier MJ,
    4. Davis RJ,
    5. Drake H,
    6. Fang FC,
    7. Gilbert J,
    8. Goldman BM,
    9. Imperiale MJ,
    10. Matsumura P,
    11. McAdam AJ,
    12. Pasetti MF,
    13. Sandri-Goldin RM,
    14. Silhavy T,
    15. Rice L,
    16. Young JA,
    17. Shenk T
    . 2016. ASM journals eliminate impact factor information from journal websites. mSphere1:e00184-16. doi:10.1128/mSphere.00184-16.
    OpenUrlFREE Full Text
  17. 17.↵
    1. Holmes J
    . 28August2015. How methods videos are making science smarter. The New Yorker, New York, NY. https://www.newyorker.com/tech/elements/how-methods-videos-are-making-science-smarter.
  18. 18.↵
    1. Schloss PD
    . 2017. Preprinting microbiology. mBio8:00438-17. doi:10.1128/mBio.00438-17.
    OpenUrlCrossRef
  19. 19.↵
    1. Imperiale MJ
    . 2016. ASM launches mSphere. mSphere1:e00006-15. doi:10.1128/mSphere.00006-15.
    OpenUrlFREE Full Text
  20. 20.↵
    1. Imperiale MJ,
    2. Shenk T,
    3. Bertuzzi S
    . 2016. mSphereDirect: author-initiated peer review of manuscripts. mSphere1:e00307-16. doi:10.1128/mSphere.00307-16.
    OpenUrlFREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
The Legacy of CVI
Marcela F. Pasetti, Steven D. Douglas, Susan F. Plaeger
Clinical and Vaccine Immunology Dec 2017, 24 (12) e00276-17; DOI: 10.1128/CVI.00276-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Legacy of CVI
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Legacy of CVI
Marcela F. Pasetti, Steven D. Douglas, Susan F. Plaeger
Clinical and Vaccine Immunology Dec 2017, 24 (12) e00276-17; DOI: 10.1128/CVI.00276-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • EDITORIAL
    • Clinical and Diagnostic Laboratory Immunology
    • Clinical and Vaccine Immunology: Expanded Scope and a New Name
    • A Springtime for CVI
    • CVI and mSphere
    • In Appreciation
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Editorial Policies
Immunoassay
immunotherapy
Periodicals as Topic
vaccines

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X